When market goes bananas, discipline always pays off if you know what to do. $clov. For long term investors enjoy the long anticipated well-deserved ride.
Federal regulators have barred three Medicare health plans operated by UnitedHealth Group Inc. and another owned by Anthem Inc. from enrolling new members next year because they didn’t spend the minimum amount required on medical benefits.
#fairhealthcare
$clov Friday they announced doubling DCE lives for 2022. Monday they announced capital raise. reason simple?
proof of operating funds
(3 month)/(12 months in a year) = 0.25
you can therefore back into their projected growth numbers. whether this changes your opinion is up to u
@pakpakchicken
@heydave7
hey guys, i've been your fans and following you guys since this whole retail investing boom since covid. I was wondering if you can take a moment to read my I'd like to hear opinions from tesla gurus on $clov =?=
#teslahealth
?
$clov i'm going to keep going every day until you allow rational supply and demand pricing of shares scarcity take place. otherwise, i'm pumping until i see a bankruptcy or bailout on bloomberg.
$clov it's actually not just about clover being cheaper. it's disrupting the incumbent web of reinsurance 15+85% gamification of revenue. this breaks the vicious inflationary cycle. this is a solution. it's not just any company, it's an idea with legs and andrewtoy.
CMS decision that so many $clov peepz are waiting for has arrived. it looks like DC program is untouched so there is risk taken off the table until end of program.
the GPDC model (next phase) is moving towards ACO+.
clover assistant = toy said agility
$clov an insider buy from Lee A. Shapiro @ cost avg. 3.1009.
He's in charge of conducting the CFO search, and was a former CFO of Livongo, a telehealth acquired by $tdoc. his vote of confidence should be viewed that the company is in sound financial health going forward.
$clov the reason why it's going up?
lvl 1: they had a revenue beat!
lvl 2:'22 Q1 is going to 2x qoq and 4x yoy
lvl N: ACO REACH is a plus for Clover Assistant, dual structure shares voting rights, and 3+ yrs of home care experience differentiates it from other MCOs as a provider
$clov pre-market is 9.77 as of 8:28 AM EST. earnings yesterday was a top line blow out. i'm not going to pump mindlessly above $10/share. so this may be the last time i can write ANDROMEDA and BEYOND!
but seriously it should be valued like an ai, disruptor, esg and rocketship.
Facts: Clover moved up and announced earnings on August 11th yesterday afternoon. The morning after announced redemption of all trade-able warrants. Warrants fell 30% due to the news.
imho If you were a hedge fund shorting $clov using $clovw as a hedge, you're bleeding right now
$clov dual crossovers still pending and on deck. fundamental value is higher per spy momentum rotation AND your stomach ulcers will disappear in a week
CRAYOLA CAPITAL ADVISORS UPGRADES $CLOV TO 60.01 CITING OVERNIGHT NONSTOP BEARISH SENTIMENT SHIFT ON STOCKTWITS STATING OBVIOUS AND IRONIC REASONS WHY BEARS SHOULD SHORT THIS COMPANY AND HAVE ZERO CONSEQUENCES AND RISK WHILE DOING SO.
back when the secondary offering was announced, i posited 3 bln rev. 2022. today $clov revised up to 3-3.4 billion! Proud of their growth.
haters be calling me names. i may suck and i may be poor but i didnt change my answer. i hope their numbers didnt change too much panicking
@AndyM50808155
clover's head is above the clouds and laser focused. better star ratings (health equity integrated), aggressive DC strategy, rich and valuable features that "delight" physicians so the assistant gets more touches and feedback. 3 Billion rev and <500ish employees. insane multiples
$clov accepting manipulation is the hardest part of investing. it's not being right and then you get rewarded. it's being right, communicating that in an articulate convincing manner, suffer humiliation, being proven right and maybe rewarded. or sell options and inverse all that.
$clov some ppl might be upset about the price action today. but be mindful of the improving price technicals and a smaller ulcer going into tomorrow's earnings. clov is healing. give it time. 🍀🚀
$clov so CMS just posted MA advanced notice. if you are into health equity, it might be a good idea to brush up on the policy end of things and contribute a little to move the industry along the curve. the next month's newsletter will open with an article on health equity preview
Looking at the future two qtr earnings: q4 2022 estimated headline yoy growth rate ~150% similar to last 3 qtrs. But check out q1 2022, 2.65bil = 660 mil per qtr. The tracking yoy rate will look like 330%. Q4 will give us insight on mcr improvement 😉 along with ~94% mcr
$clov
"...we’re seeing 35,000+ care plans managed by the Clover Assistant per month on average, hundreds of thousands of potential care gaps flagged in 2021 alone, and almost 1.7 million clinical recommendations...since the launch of the Clover Assistant"
CRAYOLA CAPITAL ADVISORS HIRED RAMEN ICHIMOKU AS HEAD ANALYST AND ISSUES NEW $CLOV PRICE TARGET AND COVERAGE AT $24.
CITING EFFICIENT FRONTIER INTERSECTION OF HC SAAS AND ITS 2021 REV/EMPLOYEE/MKTCAP SCALEABILITYFACTOR AMONG PEERS. REPORT TO FOLLOW THIS WEEK.
CRAYOLA CAPITAL ADVISORS FIRED PREVIOUS ANALYST FOR UNREALISTIC PRICE TARGET PROJECTIONS AND OFFERS A NEW $CLOV PT AT $80085. SHORT TERM COULD REACH -$10. CCA CAUTIONS ENTRY AND ENCOURAGES ALL SHORTS TO TAKE ADVANTAGE OF A GENERATIONAL OPPORTUNITY TO SHORT THIS STOCK!
$clov the leaders are looking to actively disrupt healthcare by being courageous in its redeisgn. it's not easy to rebuild something that outwardly isn't broken, at least financially. but clover treats its patients the same way it looks at the hc system: preventative & long-term
$clov i've been covering this company for over a year and it's the first time i've heard about the
1. clover health app, a revolutionary new way to sign up customers
2. $300 in cash at end of 2021
Clover's cash and cash eq was reported more than 2.5x
writin' '78, plz retire
$CLOV
The radical shift in the healthcare industry is more nuanced than a shift towards AI.
Focus shouldn't be on the tools but the philosophy of healthcare truth. Trad HC is an actuarial science with a spotty history of making right/wrong calls.
Clover is changing this. 1/n
$clov venture investing is a rough, rough turbid route of value creation. but the long term average can be competitive when you ride the turbulent waves. when you look day-to-day, it's nonsensical. $5million 2022E rev per employee. take that # to the bank when modelling inflation
$clov content to digest:
Source: The innovator's prescription by
@claychristensen
There is a deeper reason why you should be bullish about medical infotech revolution and it is because over time, disease that are intuitive-based medicine will migrate to empirical and precision
@heydave7
@freshjiva
Hey Dave,
Listened to one of your requirements: "crazy ambitions of management"
Can we set up a spaces where I can talk about $clov?
$clov Healthcare is a race. You don't decide the winner in the first 10 seconds. By the end, it's pretty clear which horse was a legendary one.
What are the metrics investors have to look into as leading indicators to spot the rev up of Clover Health?
@WealthOrDie
$clov opportune short term technicals with unbelievable shares scarcity evidenced by the option chain. 0.24% of the MA market and a top 10 with plenty of growth run way. differentiated by its silicon valley origins, it plans to achieve 2x industry margins as tech improves.
$clov, warning if you're buying into clover. it has a lot of technical breakouts ongoing but it is in extreme manipulation area. your S/Ls will get triggered. only buy if you are willing to fight at this juicy valuation.
$clov the misconception that most have about disruption is that they think technology is an instant breakthrough.
the fact is, clover's ability to serve under-served disadvantaged demographic groups by being simple and affordable w/ +5 min per doctor visit.
leverage 101 by kai
CRAYOLA CAPITAL ADVISORS FIRED PREVIOUS ANALYST FOR UNREALISTIC PRICE TARGET PROJECTIONS AND OFFERS A NEW $CLOV PT AT $80085. SHORT TERM COULD REACH -$10. CCA CAUTIONS ENTRY AND ENCOURAGES ALL SHORTS TO TAKE ADVANTAGE OF A GENERATIONAL OPPORTUNITY TO SHORT THIS STOCK!
CRAYOLA CAPITAL ADVISORS UPGRADES $CLOV TO 60.01 CITING OVERNIGHT NONSTOP BEARISH SENTIMENT SHIFT ON STOCKTWITS STATING OBVIOUS AND IRONIC REASONS WHY BEARS SHOULD SHORT THIS COMPANY AND HAVE ZERO CONSEQUENCES AND RISK WHILE DOING SO.
MARKET CAP PER EMPLOYEE
(in millions)
$42 Upstart
$39 Nvidia
$33 Netflix
$27 Shopify
$17 Tesla
$16 Apple
$16 Intuit
$14 Microsoft
$14 Meta
$13 Google
$4 Pfizer
$2 Peloton
$0.7 GE
$0.4 Ford
$0.3 IBM
$0.2 Xerox
Any observations?
$clov the story is good because when bloomberg reporter
@ZekeFaux
tries to slander the company with a copycat bear thesis but unwittingly presents a bull thesis and a new metric
#RevPerLife
2021E Rev/Life = 880M/273k =$2,930
New 2021E guidance Rev/Life = $10144.92 to $11538.46
@SophiaKianni
petroleum engineer and male here. also asian in ex-communicado with the oil and gas industry. can i get an order of racism or is this a buffet?
i sense the patriarchy vibe but i've had been burnt defending female climate science communicators in the past. conclusion: you cant